Instruction for use: Kamiren XL

Trade name of the drug – Kamiren XL

Active substance: Doxazosinum

Dosage Form: tablets

Composition (per tablet): Sustained-release tablets, film-coated tablet.

active substance:

doxazosin mesylate 4.85 mg (Equivalent to 4mg doxazosin)

Excipients: Valium - 104.01 mg; Calcium hydrogen phosphate anhydrous - 74.27 mg; lactose monohydrate - 74.27 mg; Magnesium stearate - 2.6 mg

shell film: Opadry White Y-1-7000 (Valium - 62.5%, titanium dioxide (E171) - 31.25%, macrogol 400 - 6.25%) - 13 mg

Pharmacotherapeutic group: Alpha-blockers

ATX C02CA04 Doxazosin

The nosological classification (ICD-10)

I10 Essential (primary) hypertension: hypertension; Arterial hypertension; Arterial hypertension crisis course; Essential Hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Primary hypertension; Arterial hypertension, complications of diabetes; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; arterial Hypertension; malignant Hypertension; Hypertonic disease; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; Isolated systolic hypertension

I15 Secondary hypertension: Arterial hypertension, complications of diabetes; hypertension; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; hypertension; arterial Hypertension; malignant Hypertension; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; hypertension; Arterial hypertension; Arterial hypertension crisis course; renovascular hypertension; Hypertension symptomatic; Renal hypertension; Renovascular hypertension; renovascular hypertension; Symptomatic hypertension

N40 Hyperplasia of prostate gland: Prostate adenoma; BPH; Prostatauxe; prostate Hypertrophy; Dysuric disorders caused by benign prostatic hyperplasia; Dizuricheskie disorder with benign prostatic hyperplasia; Dysuria with prostate cancer; Benign prostatic giperpalaziya; Benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2; Benign prostatic hyperplasia I degree; Benign prostatic hyperplasia II degree; Benign prostatic hypertrophy; The disease of the prostate gland; Acute urinary retention related to benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2 in combination with prostatitis; paradoxical ischuria

Pharmacological Properties of Kamiren XL

Pharmachologic effect - Mode of action - antihypertensive.

Kamiren XL Dosage and Administration

Inside, it is not liquid, squeezed small amounts of liquid during breakfast.

If reception Kamiren® CL drug skipped further the missed dose and continue to not accept the application of the scheme established by the drug.

Arterial hypertension. The recommended initial dose - 1 tab. (4 mg) once a day one. After the first dose the patient must stay in bed for 6-8 hours. It is required in relation to those likely to develop a phenomenon that first dose, is especially pronounced on application of the foregoing background diuretics.

Maximum therapeutic effect is achieved within 4 weeks of therapy. If, after 4 weeks of treatment, the effect is insufficient and the patient tolerates the drug Kamiren® CL, the dose can be increased.

The maximum daily dose - 2 tab. (8 mg) once a day one.

Benign prostatic hyperplasia. The recommended dose - 1 tab. (4 mg) once a day one. The maximum daily dose - 2 tab. (8 mg) once a day one.

Elderly patients: Dosage adjustment is not required.

Renal impairment: Dosage adjustment is not required.

Release Form

The long-acting tablets, film-coated, 4 mg. According to Table 10. in blister composite material polyamide / aluminum foil / PVC-aluminum foil coated with heat-resistant varnish (Coldforming OPA / A1 / PVC-A1) on both sides. 1, 3, 9 packaged in blister cardboard pack.

Manufacturer

Krka, dd, Novo mesto, Smarjeske cesta 6, 8501 Novo mesto, Slovenia.

To contact us at the address Office in the Russian Federation:

123022, Moscow,st.2 -d Zvenigorod, 13, p.41.

Tel .: (495) 981-10-95; fax: (495) 981-10-91.

With packaging and / or packaging of the Russian company stated:

LLC "Krka-Rus", 143500, Russia, Moscow Region., Istra Str. Moscow, 50.

Tel .: (495) 994-70-70; fax: (495) 994-70-78.

Storage conditions of Kamiren XL

The temperature is not above 30 ° C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use beyond the expiration date printed on the package.

Conditions of supply of pharmacies

On prescription.